Skip to playerSkip to main content
  • 22 minutes ago
At City of Hope, investigators are examining PANXEON, a novel blood test aimed at identifying early-stage pancreatic cancer and precancerous conditions. An international trial involving nearly 1,800 individuals from the United States, Europe, and Asia demonstrated that the test successfully recognized stage 1 and 2 pancreatic cancer 87% of the time. Additionally, it identified over 64% of high-grade dysplasia instances. The false-positive rate stood at 3% for low-risk populations and 16% for those at high risk. Ongoing research will explore how PANXEON might enhance imaging techniques and other diagnostic approaches.

Disclosure: This video contains stock footage and content created or enhanced using Al-assisted tools.
ai-generated

Category

🗞
News
Transcript
00:00Researchers are testing a new blood test designed to detect pancreatic cancer earlier.
00:04The experimental test is called Pansion.
00:07It was studied in nearly 1,800 patients across the U.S., Europe, and Asia.
00:12The test correctly identified stage 1 and 2 pancreatic cancer 87% of the time.
00:17It also detected more than 64% of high-grade dysplasia cases.
00:22That condition can represent an advanced precancerous change in the pancreas.
00:26Researchers say earlier detection could help guide decisions about further testing and treatment.
00:32Pancreatic cancer is often diagnosed late, making early detection especially difficult.
00:37About 90% of patients are diagnosed at advanced stages.
00:41Pansion combines three biological signals from a blood sample.
00:45These include two types of microRNAs and the protein CA19-9.
00:49Artificial intelligence then combines those signals into a single risk score.
00:53The test still produced false positives, especially among high-risk patients.
00:58Researchers say further evaluation is needed to determine how Pansion could complement existing diagnostic methods.
01:05Disclosure.
01:06This video contains stock footage and content created or enhanced using AI-assisted tools.
Comments

Recommended